Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide and Early-Stage Atherosclerotic Lesions in Rheumatoid Arthritis
ChiCTR2600124299Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of leflunomide in rheumatoid arthritis (RA) and atherosclerosis (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Change in carotid intima-media thickness (CIMT) at 12 months versus baseline. Planned start May 2026; status: not yet recruiting.
02
Drugs
leflunomide
03
Conditions
rheumatoid arthritis (RA)atherosclerosis
Beyond the preview
Go deeper on ChiCTR2600124299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124299.